Active replication — ongoing trial, registry, or meta-analysis.
Recent follow-up analyses of NURTURE (nusinersen) are confirming the original effect size in real-world data.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0907
Recent follow-up analyses of STR1VE (onasemnogene abeparvovec / Zolgensma) are confirming the original effect size in real-world data.
0.1077
The NURTURE (nusinersen) trial's stated primary conclusion — Presymptomatic nusinersen in SMA infants preserves motor function milestones in long-term follow-up. — replicates in independent cohorts.
0.1320
Recent follow-up analyses of LUXTURNA (voretigene) are confirming the original effect size in real-world data.
0.1436
Recent follow-up analyses of HOPE-B (Hemgenix / etranacogene) are confirming the original effect size in real-world data.
0.1443
Recent follow-up analyses of EMILIA are confirming the original effect size in real-world data.
0.1502
Recent follow-up analyses of EMERGE (aducanumab) are confirming the original effect size in real-world data.